Asim K Debnath

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8503061/publications.pdf

Version: 2024-02-01

30 papers	2,032 citations	393982 19 h-index	433756 31 g-index
34 all docs	34 docs citations	34 times ranked	2567 citing authors

#	Article	IF	Citations
1	Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays. Viruses, 2022, 14, 69.	1.5	5
2	A gossypol derivative effectively protects against Zika and dengue virus infection without toxicity. BMC Biology, 2022, 20, .	1.7	3
3	Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors. Bioorganic and Medicinal Chemistry, 2021, 32, 116000.	1.4	10
4	Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements. European Journal of Medicinal Chemistry, 2021, 224, 113681.	2.6	4
5	HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites. Journal of Medicinal Chemistry, 2021, 64, 16530-16540.	2.9	4
6	Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In Vitro. MBio, 2020, 11, .	1.8	52
7	Identification of Combinations of Protein Kinase C Activators and Histone Deacetylase Inhibitors that Potently Reactivate Latent HIV. Viruses, 2020, 12, 609.	1.5	8
8	Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation. Journal of Medicinal Chemistry, 2020, 63, 1724-1749.	2.9	31
9	Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors. Viruses, 2019, 11, 1019.	1.5	50
10	Synthesis, Antiviral Activity, and Structureâ€“Activity Relationship of 1,3â€Benzodioxolyl Pyroleâ€Based Entry Inhibitors Targeting the Phe43 Cavity in HIVâ€1 gp120. ChemMedChem, 2018, 13, 2332-2348.	1.6	14
11	Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120. European Journal of Medicinal Chemistry, 2018, 154, 367-391.	2.6	35
12	Guanidineâ€Containing Phenylâ€Pyrrole Compounds as Probes for Generating HIV Entry Inhibitors Targeted to gp120. ChemistrySelect, 2018, 3, 6450-6453.	0.7	12
13	Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. Journal of Medicinal Chemistry, 2017, 60, 3124-3153.	2.9	58
14	Synthesis of 5-Arylpyrrole-2-carboxylic Acids as Key Intermediates for NBD Series HIV-1 Entry Inhibitors. Synthesis, 2017, 49, 3692-3699.	1.2	14
15	Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity. Bioorganic and Medicinal Chemistry, 2016, 24, 5988-6003.	1.4	24
16	Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor. Bioorganic and Medicinal Chemistry, 2015, 23, 7618-7628.	1.4	10
17	Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity. Journal of Medicinal Chemistry, 2015, 58, 6909-6927.	2.9	59
18	Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41. Current Topics in Medicinal Chemistry, 2015, 16, 1074-1090.	1.0	61

#	Article	IF	Citations
19	Crystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding Site. PLoS ONE, 2014, 9, e85940.	1.1	49
20	Binding Mode Characterization of NBD Series CD4-Mimetic HIV-1 Entry Inhibitors by X-Ray Structure and Resistance Study. Antimicrobial Agents and Chemotherapy, 2014, 58, 5478-5491.	1.4	41
21	Design of antiviral stapled peptides containing a biphenyl cross-linker. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1748-1751.	1.0	23
22	Rational Design of HIV-1 Entry Inhibitors. Methods in Molecular Biology, 2013, 993, 185-204.	0.4	15
23	Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket. Viruses, 2013, 5, 127-149.	1.5	46
24	Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5663-5668.	3.3	222
25	Design, Synthesis, and Antiviral Activity of Entry Inhibitors That Target the CD4-Binding Site of HIV-1. Journal of Medicinal Chemistry, 2012, 55, 4764-4775.	2.9	83
26	Design, Synthesis, and Structureâ^'Activity Relationship of a Novel Series of 2-Aryl 5-(4-Oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 Entry Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 7631-7639.	2.9	105
27	A Cell-penetrating Helical Peptide as a Potential HIV-1 Inhibitor. Journal of Molecular Biology, 2008, 378, 565-580.	2.0	204
28	Conserved Salt Bridge between the N- and C-Terminal Heptad Repeat Regions of the Human Immunodeficiency Virus Type 1 gp41 Core Structure Is Critical for Virus Entry and Inhibition. Journal of Virology, 2008, 82, 11129-11139.	1.5	60
29	N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion. Antimicrobial Agents and Chemotherapy, 2004, 48, 4349-4359.	1.4	253
30	Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet, The, 2004, 363, 938-947.	6.3	476